12/20
07:16 am
cccc
Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology [Yahoo! Finance]
Low
Report
Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology [Yahoo! Finance]
12/19
07:42 am
cccc
C4 Therapeutics, Inc. (NASDAQ: CCCC) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $8.00.
Low
Report
C4 Therapeutics, Inc. (NASDAQ: CCCC) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $8.00.
12/8
12:30 pm
cccc
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
Low
Report
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
11/21
04:18 am
cccc
Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
Low
Report
Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
11/20
07:07 am
cccc
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
Medium
Report
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
11/20
07:00 am
cccc
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Medium
Report
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
11/18
08:50 am
cccc
C4 Therapeutics, Inc. (NASDAQ: CCCC) is now covered by analysts at Stephens. They set an "equal weight" rating and a $4.00 price target on the stock.
Medium
Report
C4 Therapeutics, Inc. (NASDAQ: CCCC) is now covered by analysts at Stephens. They set an "equal weight" rating and a $4.00 price target on the stock.
11/6
07:00 am
cccc
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
Medium
Report
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
11/5
09:00 am
cccc
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
Medium
Report
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
10/31
07:00 am
cccc
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
10/28
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/15
04:15 pm
cccc
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. [Yahoo! Finance]
High
Report
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. [Yahoo! Finance]
10/15
04:01 pm
cccc
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
High
Report
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
10/9
07:00 am
cccc
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
Low
Report
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
9/30
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)